血液透析滤过:当前临床实践与未来展望
本综述总结高容量血液透析滤过(HDF)的临床证据与实践要点,指出随机对照试验、个体参与者数据荟萃分析及大型真实世界研究显示高容量HDF较传统高通量血液透析降低全因死亡与住院,且获益呈剂量依赖,对流容量为可调控治疗目标。文章还讨论处方变量、监测指标及个体化与智能化发展方向。
要点
- 高容量HDF较传统高通量血液透析降低全因死亡和住院,获益随对流容量增加呈剂量依赖。
- 对流容量是可调控的治疗目标,应作为处方和监测的核心指标之一。
- 监测应超越小分子清除指标,纳入中分子清除和患者报告结局。
核心结论
- 当前证据支持高容量HDF是现有最有效的透析模式之一,可能成为全球肾脏替代治疗标准。
研究设计与样本
- 综述,总结随机对照试验、个体参与者数据荟萃分析及大型真实世界研究证据。
主要发现
- 高容量HDF较传统高通量血液透析降低全因死亡和住院,获益呈剂量依赖。
- 数据提示HDF在患者报告结局方面有优势,并有成本效益证据。
- 使用标准每周三次治疗方案和当代透析平台,高容量后稀释HDF可在常规临床中安全可重复实现。
关键数值与推荐
- 处方变量包括血管通路、血流量、滤过分数、治疗时间、透析器特性和机器技术。
- 监测应超越常规小分子清除指标,纳入中分子清除指标和以患者为中心的结局。
临床怎么用
- 采用高容量后稀释HDF,使用标准每周三次方案和当代透析平台。
- 将对流容量作为可调控治疗目标进行处方和监测。
- 监测中分子清除和患者报告结局,而非仅关注小分子清除。
局限性
- 实施需要基础设施、培训和质量保证投入。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemodiafiltration (HDF) with online production of substitution fluid has emerged as KRT and is increasingly adopted worldwide. Recent randomized controlled trials, individual participant data meta-analyses, and large real-world studies have demonstrated that high-volume HDF improves clinical outcomes compared with conventional high-flux hemodialysis, including reduction in all-cause mortality and hospitalization. Importantly, these benefits appear dose dependent, with achieved convective volume serving as a modifiable treatment target. Beyond survival, data suggest advantages in patient-reported outcomes and evidence for cost-effectiveness. This review provides a practical overview of contemporary HDF delivery, focusing on the prescription variables that determine treatment performance, including vascular access, blood flow rate, filtration fraction, treatment time, dialyzer characteristics, and machine technology. Current evidence suggests that high-volume postdilution HDF can be achieved safely and reproducibly in routine clinical practice using standard thrice-weekly treatment schedules and contemporary dialysis platforms. Monitoring should extend beyond conventional small-solute clearance metrics to include indicators of middle-molecule removal and patient-centered outcomes. Future developments are expected to move HDF from a uniform prescription strategy toward a more individualized approach. Emerging data support refinement of convection-volume targets according to patient characteristics and treatment response, while incorporation of patient-reported outcomes and predictive models may facilitate precision-based therapy. Advances in automation, digital monitoring, biosensors, and artificial intelligence are most likely to further optimize treatment delivery and personalization. Although implementation requires investment in infrastructure, training, and quality assurance, growing evidence suggests that these costs may be offset by improved clinical outcomes, reduced health care utilization, and enhanced sustainability. Collectively, current evidence supports high-volume HDF as among the most effective dialysis modalities currently available, and it is likely to become the global standard for KRT.
引用
- Blankestijn PJ, Roos S, Barth C, et al. Hemodiafiltration: Clinical Practice of Today and a Look into the Future. J Am Soc Nephrol. 2026. PMID: 42771831. doi:10.1681/ASN.0000001282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。